❌ The myth: AI is transforming medical devices.
Right now. On scale. Consequently, the conference keynotes say so. The investor decks confirm it. As a result – if you are not already deploying AI, you are falling behind.
The data tells a different story.
Still Mostly in the Pilot Phase
The global market for AI-enabled medical devices is projected at $18.9 billion in 2025, and approval numbers are climbing. However, within companies, the picture is far less impressive. A 2024 survey of MedTech executives found that although roughly two-thirds say their companies are implementing generative AI, about half remain in the pilot phase and fewer than 20 per cent are genuinely scaling with successful results.
First thing to remember: Pilots are not products. And in a regulated industry, the distance between the two is substantial.
The Regulatory Barrier Nobody Wants to Talk About
AI adoption in MedTech has been forced into a plodding pattern in the face of regulatory compliance. This with concerns around risk classification, transparency, data quality, potential bias, and integration into existing workflows challenging regulatory bodies, before even considering AI adaptability and the need for re-authorization.
Unquestionably, in the EU, the situation has become more complex. AI systems embedded in medical devices that qualify as high-risk under the AI Act must now comply with requirements that go above and beyond those already demanded by MDR and IVDR. Manufacturers are not navigating one framework; in fact they are navigating two, simultaneously, with limited harmonized guidance and shrinking notified body capacity.
MedTech Europe has been direct: without clearer rules, manufacturers risk being caught between overlapping legal requirements, unclear definitions, and regulatory bottlenecks that delay patient access to technologies that are, in principle, already safe and effective.
The Strategy Gap Is the Real Problem
Technology readiness is not a constraint. Strategic readiness is. Among MedTech companies already deploying AI, nearly one third admit they do not know how to prioritize use cases. MedTech leaders are 40 per cent more likely than their pharma counterparts to lack an effective AI implementation strategy altogether.
Meanwhile, only 61 per cent of organizations using predictive AI models had tested them on their own patient data and fewer still had evaluated those models for bias. These are not edge cases. They are the norms.
The Bottom Line
AI in MedTech is not a revolution happening now. It is a transition one that will reward companies that approach it methodically and penalize those chasing the hype without the regulatory and quality foundations to back it up. The bottleneck is not an algorithm. It is the regulatory strategy, quality system integration, and compliance of readiness to bring AI to market in a validated, audit-ready form.
Where AIMEDIQ Fits
This is precisely the gap AIMEDIQ was built to address. Regulatory intelligence on AI in MedTech covering the EU AI Act, MDR/IVDR intersections, FDA guidance on AI/ML-enabled devices, and more is available within a closed, source-referenced system. No generic AI hallucinations. No trawling through guidance documents manually. Just traceable, audit-ready answers when your team needs them.
If your organization is serious about AI integration, the regulatory homework comes first. AIMEDIQ helps you do it properly. www.eumediq.eu/aimediq
Key Takeaway
Most MedTech companies are nowhere near scaled AI deployment, and regulatory complexity is the primary reason. In the EU, parallel obligations under MDR/IVDR and the AI Act create a compliance burden that cannot be solved by technology alone. Companies that invest in regulatory strategy and quality system readiness first will reach the market. Those that do not remain in the pilot phase indefinitely.